On November 17, the Canadian Department of Health reported 36 serious reactions to H1N1 vaccines among the 6.6 million people vaccinated. These side effects, outbreaks of high fever and serious allergic reactions (including one fatal case) were not considered worrying by the health authorities. “To date, the frequency of cases of anaphylaxis is less than one case per 100,000 doses distributed and therefore does not exceed the rates associated with other vaccines,” it was written in the bulletin.
Everything accelerated Tuesday, when the WHO, revealed “an unusual number of serious allergic reactions” in Canadians immunized by a batch produced by the laboratory GlaxoSmithKline (GSK). “Canadian regulatory agencies, which as in other countries monitor the occurrence of adverse reactions in real time, have identified a five-fold higher level of anaphylactic reactions, or 1 in 20,000, in people who received a particular batch of the vaccine. Arepanrix, specifies Dr. Soizic Courcier, spokesperson for GSK. This suspect batch, which represents 170,000 doses, has been suspended for analyzes. “
Corn:
“Whether it is a vaccine or a drug, the recall of a batch is not an exceptional phenomenon, it is part of the quality chain”, further notes the spokesperson for GSK. “Allergies to egg proteins, used to produce influenza vaccines, are exceptional.”
